Anti-LRRK2 antibody (ab31546)

Overview

• Product nameAnti-LRRK2 antibodySee all LRRK2 primary antibodies ...
• Description
  Sheep polyclonal to LRRK2
• Tested applicationsIHC-P, IHC-Fr more details
• Species reactivity
  Reacts with: Human
  Predicted to work with: Mouse
• Immunogen

  Synthetic peptide LKRKRKILSSDDSLRSS, corresponding to amino acids 946-962 of Human LRRK2 conjugated to a highly immunogenic molecule, Blue Carrier Protein.

  Run BLAST with Run BLAST with
• Positive controlIHC-P and IHC-Fr: normal and diseased human brain.

Properties

• FormLiquid
• Storage instructionsStore at +4°C short term (1-2 weeks). Aliquot and store at -20°C or -80°C (add glycerol to a final volume of 50% for extra stability). Avoid repeated freeze / thaw cycles.
• Storage bufferPreservative: None
  Constituents: Whole serum
• PurityWhole antiserum
• Clonality Polyclonal
• IsotypeIgG
• Research Areas
  • Neuroscience
  • Neurology process
  • Neurodegenerative disease
  • Parkinson's disease
  • Synuclein

Applications

Target

• FunctionMay play a role in the phosphorylation of proteins central to Parkinson disease. Phosphorylates PRDX3. May also have GTPase activity. Positively regulates autophagy through a calcium-dependent activation of the CaMKK/AMPK signaling pathway. The process involves activation of nicotinic acid adenine dinucleotide phosphate (NAADP) receptors, increase in lysosomal pH, and calcium release from lysosomes.
• Tissue specificityExpressed throughout the adult brain, but at a lower level than in heart and liver. Also expressed in placenta, lung, skeletal muscle, kidney and pancreas. In the brain, expressed in the cerebellum, cerebral cortex, medulla, spinal cord occipital pole, frontal lobe, temporal lobe and putamen. Expression is particularly high in brain dopaminoceptive areas.
• Involvement in diseaseParkinson disease 8 (PARK8) [MIM:607060]: A slowly progressive neurodegenerative disorder characterized by bradykinesia, rigidity, resting tremor, postural instability, neuronal loss in the substantia nigra, and the presence of neurofibrillary MAPT (tau)-positive and Lewy bodies in some patients. Note=The disease is caused by mutations affecting the gene represented in this entry.
• Sequence similaritiesBelongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family.
  Contains 12 LRR (leucine-rich) repeats.
  Contains 1 protein kinase domain.
  Contains 1 Roc domain.
• Post-translational
  modificationsAutophosphorylated.
• Cellular localizationCytoplasm. Membrane. Mitochondrion. Localized in the cytoplasm and associated with cellular membrane structures. Associates with the mitochondrial outer membrane.

Target information above from: UniProt accession Q5S007 The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010) .

Information by UniProt
• Database links
  • Entrez Gene: 120892 Human
  • Entrez Gene: 66725 Mouse
  • Omim: 609007 Human
  • SwissProt: Q5S007 Human
  • SwissProt: Q5S006 Mouse
  • Unigene: 187636 Human
  • Unigene: 37558 Mouse

• Alternative names
  augmented in rheumatoid arthritis 17 antibodyAURA17 antibodyDardarin antibody

  Leucine rich repeat kinase 2 antibodyLeucine-rich repeat serine/threonine-protein kinase 2 antibodyLRRK 2 antibodyLRRK2 antibodyLRRK2_HUMAN antibodyPARK 8 antibodyPARK8 antibodyRIPK7 antibodyROCO 2 antibodyROCO2 antibody

  see all